The activity of the human immunodeficiency virus (HIV) protease is essential for processing of the gag-pol precursor proteins and maturation of infectious virions. We have prepared a peptidomimetic inhibitor, U-75875, that inhibited HIV-1 gag-pol protein processing in an essentially irreversible manner. Noninfectious virus particles produced in the presence of the drug contained gag precursors and were morphologically immature. In human peripheral blood mononuclear cells and in a continuous cell line, U-75875 completely blocked HIV replication; in the latter case, no spread occurred over a period of 4 weeks. U-75875, on a molar basis, was as potent as 3'-azido-3'-deoxythymidine in blocking HIV-1 replication in human lymphocytes and also inhibited HIV-2 and simian immunodeficiency virus proteases, demonstrating that it has broad activity. These results provide further evidence for the therapeutic potential of protease inhibitors in HIV infection.
The expanding AIDS epidemic and the relentless nature of the disease have created a desperate need for effective anti-viral therapies to control the replication of the human immunodeficiency virus (HIV) in infected patients. One attractive target for specific anti-viral therapy is the protease, encoded by the pol gene of HIV (1, 2) . This aspartic protease (3) (4) (5) (6) (7) (8) (9) cleaves the viral p55 gag precursor into the four structural proteins of the virion core (p17, p24, p8, and p7); additionally, protease activity is required for cleavage of the p160 gag-pol precursor, which yields protease itself, reverse transcriptase (RT) , and endonuclease as well as structural proteins (10) . Such processing of the HIV gag and gag-pol precursor polyproteins is essential for the maturation of infectious virions (11) (12) (13) (14) .
Synthetic peptidomimetic HIV-1 protease inhibitors, containing a nonhydrolyzable synthetic replacement of the Pj-Pt scissile amide bond, bind to the protease, interfere with the processing of the HIV-1 p55 gag precursor in mammalian cells, and block HIV replication in human T lymphocytes (15) (16) (17) . However, our studies with one of these compounds, U-81749 {Tba-Cha-T[CH(OH)CH2]-Val-Ile-Amp; where Tha is tert-butylacetyl, Cha is cyclohexylalanine, and Amp is 2-aminomethylpyridine}, indicated that protease inhibition in isolated particles was reversed within a few hours by diluting them in drug-free medium (15) . The latter property was useful in establishing that the protease was the target of the inhibitor but undesirable for potential antiviral therapy. We sought, therefore, to identify more potent peptidomimetic HIV-1 protease inhibitors with less reversible activities.
MATERIALS AND METHODS
Cell Lines Used. H9/HTLVIIIB (a gift of M. RobertGuroff, National Cancer Institute, National Institutes of Health) is a human T-cell line chronically infected with HIV-lHTLVIIIB that continuously produces infectious virions.
CEMx174 (a gift of P. Marx, University of California-Davis Primate Center) is a human T-lymphocyte/B-lymphocyte hybrid cell line that is readily infected and killed by HIV or simian immunodeficiency virus (SIV). MT-4 is an uninfected human T-lymphocyte cell line (18, 19) (Fig. 2) , indicating that this drug did not markedly alter the number of particles released from the infected cells. Significantly, 1 ,uM U-75875 completely blocked the processing of p55 to p24, at 0.1 ,uM U-75875 partial inhibition was observed. The inhibition of p55 processing in HIV-1 particles by U-75875 was confirmed using an HIV-1 p24 antigen-capture ELISA that efficiently detects p24 but not p55. HIV-1 particles produced in the presence of0.1-1 ,uM U-75875 also were deficient in RT activity (20-40% that of control particles), indicating that proper protease function is required for p160 gag-pol precursor processing and full RT activity (Fig. 2) . To investigate the kinetics of the protease inhibition, we repeated the experiment using 1 uM U-75875 and collected supernatants containing particles formed during the following times 0-3, Table 1 
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Ki determination for inhibition of recombinant HIV-1 protease activity was performed as described (15) . Tha, tert-butylacetyl; Boc, tert-butyloxycarbonyl; Poa, phenoxyacetyl; Noa, 1-naphthoxyacetyl; Amp, 2-aminomethylpyridine; Mba, (2S)-methylbutylamine; Leu Fig. 3 , inhibition of p55 processing by U-75875 was evident 3 hr after the addition of the compound; by 24 hr the inhibition was almost complete.
-T[CH(OH)CH(OH)]-Val, (5S)-amino-(3R,4R)-dihydroxy-(2R)-isopropyl-7-methyloctanoyl; Cha-T[CH(OH)CH(OH)]-Val, (5S)-amino-6-cyclohexyl-(3R,4R)-dihydroxy-(2R)-isopropylhexanoyl;
Virus Particles Produced in the Presence of U-75875 Are Immature and Noninfectious. To further investigate the effects of inhibition of gag and gag-pol processing, we analyzed the particle morphology and infectivity. Electron microscopic analysis of control H9/HTLVIIIB cells revealed principally mature virions, characterized by a thin envelope structure, both outside the cells and in cytoplasmic vacuoles. In some particles, depending on the plane of the section, dense nucleoids were visible. In contrast and with few exceptions, the particles observed in the cells cultured with 1 ,uM U-75875 had an immature morphology, characterized by thick ring-shaped nucleoids (Fig. 4) . By using a human MT-4 lymphocyte end-point assay, we determined that the untreated H9/ HTLVIIIB cells released moderate amounts ofinfectious HIV particles (titer = 3.2 x 103 TCID50 per ml of supernatant). Significantly, supernatants recovered from cells incubated with 1 puM U-75875 contained no detectable infectious HIV (titer < 32 TCID50 per ml), despite a comparable total particle number as indicated by the protein analysis of these supernatants shown in Fig. 3 , sample at 24-48 hr. Under these conditions, HIV killed about 85% of the CD4-positive cells within 6 days in cultures without drug. Significantly, 1 ,uM U-75875 completely blocked the spread of HIV-1 infection, as measured by supernatant RT and p24 (Fig. 5) . A separate experiment directly comparing the antiviral potency of U-75875 to that of 3'-azido-3'-deoxythymidine as well as to U-81749 indicated that, on a molar basis, U-75875 was as potent as 3'-azido-3'-deoxythymidine and considerably more potent than U-81749 (data not shown). Additionally U-75875 displayed no nonspecific toxicity on PBMCs even at 10,uM (the highest concentration tested; data not shown).
The above experiments were of limited duration since, even in the presence of interleukin 2, PBMCs can only be maintained in culture for a defined period. To study the anti-HIV effect of U-75875 over a longer time, we infected continuously growing CEMx174 cells with HIV-lLAv and H9/HTLVIIIB cells were incubated in the presence (+) or absence (-) of 1 ,uM U-75875. Supernatants were harvested and the cells were resuspended in fresh drug-containing medium at 3-hr intervals. A supernatant between 24 and 48 hr was obtained from a separate experiment in which H9/HTLVIIIB cells were incubated for 48 hr in the presence or absence of 1 AM U-75875 for 24 hr with a wash and medium change at 24 hr. Supernatants were processed and analyzed for gag processing on a protein immunoblot, as described in Fig. 2 (Fig. 6 ).
The homology of the HIV-2 and SIV proteases with the HIV-1 enzyme (24) and the ability of U-75875 to inhibit HIV-2 protease in vitro (Ki, 30 nM) led us to investigate the effects of U-75875 on the spread of SIVmac251 in CEMx174 cells. As with HIV-1 infection, SIV spread was completely blocked during the 4-week period of the experiment whereas untreated cells were rapidly killed by the virus (Fig. 6 ). In addition, U-875875 inhibited HIV-2 maturation in CEMx174 cells chronically infected with HIV-2 (data not shown).
DISCUSSION
HIV-1 protease belongs to the mechanistic class of aspartic proteases (3) (4) (5) (6) (7) (8) (9) . Earlier studies with other members of this family, such as human renin or pepsin, showed that synthetic peptidomimetic compounds containing a hydroxyethylene isosteric insert as a nonhydrolyzable synthetic replacement of the Pj-Pt scissile amide bond are able to inhibit the catalytic function of such proteases (25, 26) . Consequently, peptidomimetic HIV-1 protease inhibitors were prepared and found to inhibit the processing ofthe HIV-1 p55 gag precursor protein to the p24 and p17 core proteins (15, 16) . In this communication, we describe an inhibitor, U-75875, that on a molar basis is equipotent to 3'-azido-3'-deoxythymidine and considerably more potent than the protease inhibitor U-81749 (15) in blocking HIV replication in primary human lymphocytes. Significantly, U-75875 inhibited maturation of three related primate lentiviruses: HIV-1, HIV-2, and SIVmac.
We found that U-75875 efficiently and irreversibly prevented gag processing in particles produced by cells infected with a recombinant vaccinia virus encoding the HIV-1 gagpol polyproteins as well as by HIV-1 chronically infected human T cells. Thus, virions released in the presence of the protease inhibitor contained p55, little or no p24, and reduced RT. In addition, these virus particles had an immature appearance and were noninfectious.
The strong anti-HIV activity of the protease inhibitor U-75875 was demonstrated in spreading infection experiments. In primary cells as well as in continuous cell lines, concentrations significantly lower than those required for PBMC toxicity were able to completely block the spread of infection for at least 1 month. Moreover, our initial experiments in rodents indicated that concentrations of U-75875 exceeding those required for in vitro anti-HIV activity can be maintained for several hours without any visible signs of toxicity (M. J. Ruwart, personal communication). These results, and findings reported by others (17) , provide evidence that this class of compounds may have a wide therapeutic margin and hold promise for the treatment of HIV infection in vivo.
